Results 101 to 110 of about 32,827 (233)

MRP2 as a Targetable Oxaliplatin Resistance Factor in Gastrointestinal Cancer

, 2018
Despite the severe adverse effects, toxicity and limited efficacy due to the development of multidrug resistance (MDR), chemotherapy is still the treatment of choice for most of the cancer patients.
Biswas, Riya
core   +1 more source

miR-135a promotes gastric cancer progression and resistance to oxaliplatin

Oncotarget, 2016
Resistance to oxaliplatin (OXA)-based chemotherapy regimens continues to be a major cause of gastric cancer (GC) recurrence and metastasis. We analyzed GC samples and matched non-tumorous control stomach tissues from 280 patients and found that miR-135a was overexpressed in GC samples relative to control tissues.
Yan, Lin-Hai, Chen, Zhi-Ning, Li-Li,, Chen, Jia, Wei, Wen-E, Mo, Xian-Wei, Qin, Yu-Zhou, Lin, Yuan, Chen, Jian-Si   +8 more
openaire   +3 more sources

Transcriptome‐Based Classification of Resected Pancreatic Ductal Adenocarcinoma Enhances Prognostic Modelling Accuracy of Overall Survival Following Adjuvant Treatment

International Journal of Cancer, EarlyView.
Outcomes after resection of pancreatic ductal adenocarcinoma remain highly variable, and existing prognostic models lack sufficient accuracy. Here, the authors aimed to improve survival prediction by integrating transcriptome‐based subtyping into a validated clinical model and applying it to a multicenter real‐world cohort of fresh‐frozen resection ...
Marjolein F. Lansbergen, Vincent R. Lanting, Paul Manoukian, Marc G. Besselink, Geert Kazemier, Ignace H. J. T. de Hingh, Mike S. L. Liem, Casper H. J. van Eijck, Erwin van der Harst, Vincent E. de Meijer, Ronald M. van Dam, Martijn W. J. Stommel, Jan Koster, Michael W. T. Tanck, Arantza Fariña Sarasqueta, Joanne Verheij, Frederike Dijk, Johanna W. Wilmink, Maarten F. Bijlsma, Hanneke W. M. van Laarhoven, for the Dutch Pancreatic Cancer Group   +20 more
wiley   +1 more source

Tumor‐Regional Immune Microenvironment: A Critical Factor in the Design of Radiotherapy–Immunotherapy Combination Trials

International Journal of Cancer, EarlyView.
ABSTRACT Clinical trials combining radiotherapy (RT) with immune checkpoint blockade (ICB) have shown improved outcomes in only a fraction of patients, and optimal strategies for integrating these modalities remain under intense investigation. With a few exceptions, phase III combination trials have yielded disappointing results.
Xuanwei Zhang, Hui Wang, Weiyan Tang, Kai Kang, Kateryna Onyshchenko, Taotao Huang, Dan Liu, Jianxin Xue, You Lu, Gabriele Niedermann, Ren Luo   +10 more
wiley   +1 more source

Predictive Biomarkers in Metastatic Colorectal Cancer Patients Treated With Bevacizumab: A Turkish Oncology Group (TOG) Study

International Journal of Cancer, EarlyView.
Bevacizumab added to systemic chemotherapy remains a cornerstone of metastatic colorectal cancer treatment, but its effectiveness is variable. Tumors can bypass the VEGF blockade by activating other pro‐angiogenic pathways, hampering the identification of predictive biomarkers.
Büsra Akay Hacan, Fatma Gizem Sonugür, Müge Öçal, Cansu Babahan, Samira Abgarmi, Ülkü Yalçıntaş Arslan, Mehmet Ali Şendur, Ahmet Demirkazık, Güngör Utkan, Hakan Akbulut   +9 more
wiley   +1 more source

Cross resistance between cisplatin and oxaliplatin in a low-level resistance lung cancer cell model

, 2005
Oxaliplatin is thought to have activity against cisplatin resistant cancers and has fewer side effects than cisplatin. An understanding of the cellular and molecular reasons for this advantage would lead to further treatment improvements. A lack of cross
Stordal, B., Davey, M., Davey, R.
core  

MET Expression in Upper Gastrointestinal Adenocarcinoma: Prevalence, Prognostic Impact, and Implications for Anti‐MET Antibody‐Drug Conjugate Therapy

International Journal of Cancer, EarlyView.
ABSTRACT MET is an actionable receptor tyrosine kinase, and MET‐directed antibody–drug conjugates (ADCs) have recently entered clinical practice with FDA approval in non‐small cell lung cancer and are now being evaluated across gastrointestinal malignancies, with patient selection based on MET immunohistochemistry (IHC) 3+ membranous staining at ...
Tillmann Bedau, Thomas Zander, Hans Anton Schlößer, Hakan Alakus, Onur Mustafov, Reinhard Büttner, Christiane Bruns, Alexander Quaas   +7 more
wiley   +1 more source

Downregulation of AC092894.1 promotes oxaliplatin resistance in colorectal cancer via the USP3/AR/RASGRP3 axis

, 2023
Background Oxaliplatin resistance is a complex process and has been one of the most disadvantageous factors and indeed a confrontation in the procedure of colorectal cancer. Recently, long non-coding RNAs (lncRNAs) have emerged as novel molecules for the
Ming Wu, Kailing Pan, Ting Jiang, Mengxiang Yang, Xiayun Jin, Jianfei Fu, Linchao Ding, Hongyan Li, Hongjuan Zheng, Wenxia Xu, Yanfei Zhang, Zhijian Zheng, Yuqi Ni   +12 more
core   +1 more source

Metal‐dependent regulated cell death: Molecular architecture and translational frontiers

iMeta, EarlyView.
Intracellular metal dyshomeostasis orchestrates distinct regulated cell death programs, including iron‐driven ferroptosis, copper‐mediated cuproptosis, calcicoptosis, newly designated zincoptosis, mnoptosis, and coptosis. This review systematically delineates their molecular architectures—spanning from Sorafenib‐induced lipid peroxidation and ...
Haoliang Hu, Zhe Chen, Yaqi Li, Jiayi Peng, Jiangang Cao, Hong Zhou, Mengqi Wang, Yuejia Du, Hailin Wu, Huiqin Zhao, Shifang Huang, Dianmei Yu, Meiqing Liu, Olga V. Shevchenko, Natalia Yu. Matveeva, Yiyuan Yang, Kerui Huang, Deguan Lv, Junxia Min, Linxi Chen, Fudi Wang   +20 more
wiley   +1 more source

Early responses of the STAT3 pathway to platinum drugs are associated with cisplatin resistance in epithelial ovarian cancer

Brazilian Journal of Medical and Biological Research, 2013
Cisplatin resistance remains one of the major obstacles when treating epithelial ovarian cancer. Because oxaliplatin and nedaplatin are effective against cisplatin-resistant ovarian cancer in clinical trials and signal transducer and activator of ...
W.J. Sheng, H. Jiang, D.L. Wu, J.H. Zheng   +3 more
doaj   +1 more source